COREX combines TB-500 and BPC-157, two experimental peptides investigated in preclinical research involving cellular signaling, tissue repair, vascular responses, and biological recovery pathways. Human clinical evidence remains limited, and the combination is not an established approved therapy. Claims regarding injury healing, athletic recovery, or performance enhancement should therefore not be presented as clinically established benefits.